● 增加 ADC 向肿瘤组织输送:如抗血管生成药物可能通过促进肿瘤血管正常化来改善 ADC 向肿瘤组织的输送,提高 ADC 的细胞毒性作用;
● 调节抗体靶蛋白表达:增加肿瘤细胞表面靶抗原表达的药物可能会促进抗体抗原结合;同时增强抗原转换或降解的药物可能会促进 ADC 的摄取和有效载荷的切割和释放,从而增强细胞毒性;
● 增强有效载荷活动和/或合成杀伤:通过互补机制或合成杀伤力发挥协同作用的其他药物可增强有效载荷活动;
探索 ADC 药物联合策略治疗乳腺癌
ADC 药物联合方案的未来发展方向
全文完,如果觉得内容不错,那就点个赞或者「在看」吧,最好能加个星标🌟,因为微信最近改版了,多谢阅读。
整理:黄玉庭;审核:曹文明教授
排版:林舒雅;插图:曹文明教授讲课 PPT
参考文献: 1、Nicolò E, Giugliano F, Ascione L, et al. Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives. Cancer Treat Rev. 2022;106:102395. 2、Fuentes-Antrás J, Genta S, Vijenthira A, Siu LL. Antibody-drug conjugates: in search of partners of choice. Trends Cancer. 2023;9(4):339-354. 3、Emens LA, Esteva FJ, Beresford M, et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncol. 2020;21(10):1283-1295. 4、Perez EA, Barrios C, Eiermann W, et al. Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE. Cancer. 2019 Nov 15;125(22):3974-3984. 5、Harbeck N, Im SA, Barrios CH, et al. Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC). Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 500-500. 6、Erika Hamilton,Charles L. Shapiro, Daniel Petrylak,et al.Trastuzumab deruxtecan (T-DXd; DS-8201) with nivolumab in patients with HER2-expressing advanced breast cancer: a 2-part, phase 1b, multicenter, open-label study. 2020 SABCS. PD3-07. 7、Peter Schmid, Seock-Ah Im, Anne Armstrong, et al. BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd). 2021ASCO. 1023. 8、Hurvitz SA, Martin M, Jung KH, et al. Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study. J Clin Oncol. 2019 Sep 1;37(25):2206-2216. 9、Modi S, et al. Antitumor activity and safety of trastuzumab deruxtecan in rptients with her2-low–expressing advanced breast cancer: results from a phase Ib study. J. Clin. Oncol. 2020;38(17):1887–1896.
联系客服